Serum protein profiling of early and advanced stage Crohn's disease

Baumgart, 2007, Inflammatory bowel disease: clinical aspects and established and evolving therapies, The Lancet, 369, 1641, 10.1016/S0140-6736(07)60751-X Baumgart, 2007, Inflammatory bowel disease: cause and immunobiology, The Lancet, 369, 1627, 10.1016/S0140-6736(07)60750-8 Presley, 2012, Host–microbe relationships in inflammatory bowel disease detected by bacterial and metaproteomic analysis of the mucosal–luminal interface, Inflammatory Bowel Diseases, 18, 409, 10.1002/ibd.21793 Erickson, 2012, Integrated metagenomics/metaproteomics reveals human host–microbiota signatures of Crohn's disease, PLoS ONE, 7, e49138, 10.1371/journal.pone.0049138 Travis, 2006, European evidence based consensus on the diagnosis and management of Crohn's disease: current management, Gut, 55, i16, 10.1136/gut.2005.081950b Iskandar, 2012, Biomarkers in inflammatory bowel disease: current practices and recent advances, Translational Research, 159, 313, 10.1016/j.trsl.2012.01.001 Lewis, 2011, The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease, Gastroenterology, 140, 1817, 10.1053/j.gastro.2010.11.058 Tibble, 2002, Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease, Gastroenterology, 123, 450, 10.1053/gast.2002.34755 Fagerhol, 2000, Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease, Gastroenterology, 119, 15, 10.1053/gast.2000.8523 Tibble, 2001, Non-invasive investigation of inflammatory bowel disease, World Journal of Gastroenterology, 7, 460, 10.3748/wjg.v7.i4.460 Vermeire, 2004, C-reactive protein as a marker for inflammatory bowel disease, Inflammatory Bowel Diseases, 10, 661, 10.1097/00054725-200409000-00026 Meuwis, 2007, Biomarker discovery for inflammatory bowel disease: using proteomic serum profiling, Biochemical Pharmacology, 73, 1422, 10.1016/j.bcp.2006.12.019 Vermeire, 2001, Comparative study of ASCA (Anti-Saccharomyces cerevisia antibody) assays in inflammatory bowel disease, Gastroenterology, 120, 827, 10.1053/gast.2001.22546 Joossens, 2004, Interassay and interobserver variability in the detection of anti-neutrophil cytoplasmic antibodies in patients with ulcerative colitis, Clinical Chemistry, 50, 1422, 10.1373/clinchem.2004.032318 Joossens, 2002, The value of serologic markers in indeterminate colitis: a prospective follow-up study, Gastroenterology, 122, 1242, 10.1053/gast.2002.32980 Klebl, 2003, Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with vienna classification subtypes of Crohn's disease, Inflammatory Bowel Diseases, 9, 302, 10.1097/00054725-200309000-00003 Bene, 2003, High normal serum levels of C3 and C1 inhibitor: two acute-phase proteins belonging to the complement system, occur more frequently in patients with Crohn's disease than ulcerative colitis, Digestive Diseases and Sciences, 48, 1186, 10.1023/A:1023793502456 Weeke, 1971, Serum concentration of 19 serum proteins in Crohn's disease and ulcerative colitis, Gut, 12, 297, 10.1136/gut.12.4.297 Monteleone, 2014, Tissue inhibitor of metalloproteinase-3 regulates inflammation in human and mouse intestine, Gastroenterology, 143, 1277, 10.1053/j.gastro.2012.07.016 Kugathasan, 2007, Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease, Gut, 56, 1696, 10.1136/gut.2006.116467 Baert, 2010, Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease, Gastroenterology, 138, 463, 10.1053/j.gastro.2009.09.056 D‘Haens, 2008, Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial, The Lancet, 371, 660, 10.1016/S0140-6736(08)60304-9 Görg, 2004, Current two-dimensional electrophoresis technology for proteomics, Proteomics, 4, 3665, 10.1002/pmic.200401031 Gaviraghi, 2010, Proteomics to investigate fertility in bulls, Veterinary Research Communications, 34, 33, 10.1007/s11259-010-9387-0 Yan, 2000, A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry, Electrophoresis, 21, 3666, 10.1002/1522-2683(200011)21:17<3666::AID-ELPS3666>3.0.CO;2-6 D‘auria, 2005, Proteomic evaluation of milk from different mammalian species as a substitute for breast milk, Acta Paediatrica, 94, 1708, 10.1080/08035250500434793 Roncada, 2009, Proteomic study of antibiotic resistance in Escherichia coli strains, Veterinary Research Communications, 33, 157, 10.1007/s11259-009-9260-1 Turk, 2012, Proteomics of inflammatory and oxidative stress response in cows with subclinical and clinical mastitis, Journal of Proteomics, 75, 4412, 10.1016/j.jprot.2012.05.021 Bortolato, 2012, NMDARs mediate the role of monoamine oxidase A in pathological aggression, Science Signalling, 32, 8574 Scambi, 2010, Comparative proteomic analysis of serum from patients with systemic sclerosis and sclerodermatous GVHD. Evidence of defective function of factor H, PLoS ONE, 5, e12162, 10.1371/journal.pone.0012162 Molmenti, 1993, Cell-specific expression of alpha 1-antitrypsin in human intestinal epithelium, Journal of Clinical Investigation, 92, 2022, 10.1172/JCI116797 Folwaczny, 1998, a1-Antitrypsin alleles and phenotypes in patients with inflammatory bowel disease, Scandinavian Journal of Gastroenterology, 33, 78, 10.1080/00365529850166248 Taddei, 1999, Alpha1-antitrypsin phenotypes and anti-neutrophil cytoplasmic auto-antibodies in inflammatory bowel disease, European Journal of Gastroenterology & Hepatology, 11, 1293, 10.1097/00042737-199911000-00019 Kotlowski, 2008, Population-based case–control study of alpha 1-antitrypsin and SLC11A1 in Crohn's disease and ulcerative colitis, Inflammatory Bowel Diseases, 14, 1112, 10.1002/ibd.20425 Elphick, 2008, Impaired luminal processing of human defensin-5 in Crohn's disease: persistence in a complex with chymotrypsinogen and trypsin, The American Journal of Pathology, 172, 702, 10.2353/ajpath.2008.070755 Halstensen, 1989, Persistent complement activation in submucosal blood vessels of active inflammatory bowel disease: immunohistochemical evidence, Gastroenterology, 97, 10, 10.1016/0016-5085(89)91409-1 Volanakis, 1998 Scheinin, 1999, Decreased expression of protectin (CD59) in gut epithelium in ulcerative colitis and Crohn's disease, Human Pathology, 30, 1427, 10.1016/S0046-8177(99)90163-6 Nielsen, 1978, Circulating immune complexes in ulcerative colitis. I. Correlation to disease activity, Clinical and Experimental Immunology, 31, 72 Petersen, 1988, Activation of classical pathway complement in chronic inflammation, Acta Medica Scandinavica, 223, 557, 10.1111/j.0954-6820.1988.tb17695.x Ueki, 1996, Distribution of activated complement: C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC), Clinical & Experimental Immunology, 104, 286, 10.1046/j.1365-2249.1996.17721.x Halstensen, 1993, Epithelial deposits of immunoglobulin G1 and activated complement colocalise with the M (r) 40kD putative autoantigen in ulcerative colitis, Gut, 34, 650, 10.1136/gut.34.5.650 Halstensen, 1992, Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis, Gut, 33, 902, 10.1136/gut.33.7.902 Erik, 2005, Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis, BMC Gastroenterology, 5, 31, 10.1186/1471-230X-5-31 Zimmermann-Nielsen, 2003, Complement activation in plasma before and after infliximab treatment in Crohn disease, Scandinavian Journal of Gastroenterology, 38, 1050, 10.1080/00365520310005767 Laufer, 2000, Cellular localization of complement C3 and C4 transcripts in intestinal specimens from patients with Crohn's disease, Clinical & Experimental Immunology, 120, 30, 10.1046/j.1365-2249.2000.01168.x Ahrenstedt, 1990, Enhanced local production of complement components in the small intestines of patients with Crohn's disease, New England Journal of Medicine, 322, 1345, 10.1056/NEJM199005103221903 Simonsen, 1985, Defective modulation of complement in Crohn's disease: C3b opsonization of zymosan by the alternative pathway, Scandinavian Journal of Gastroenterology, 20, 883, 10.3109/00365528509088840 Hodgson, 1977, C3 metabolism in ulcerative colitis and Crohn's disease, Clinical and Experimental Immunology, 28, 490 Del Chierico, 2012, Early-life gut microbiota under physiological and pathological conditions: the central role of combined meta-omics-based approaches, Journal of Proteomics, 75, 4580, 10.1016/j.jprot.2012.02.018 Jenne, 1992, Clusterin: the intriguing guises of a widely expressed glycoprotein, Trends in Biochemical Sciences, 17, 154, 10.1016/0968-0004(92)90325-4 Trougakos, 2006, Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases, Free Radical Research, 40, 1324, 10.1080/10715760600902310 Gassler, 2001, Expression of clusterin in Crohn's disease of the terminal ileum, Histol Histopathol, 16, 755 Trougakos, 2009, Oxidative stress in malignant progression: the role of clusterin, a sensitive cellular biosensor of free radicals, Advances in Cancer Research, 104, 171, 10.1016/S0065-230X(09)04009-3 Antonelou, 2011, Apolipoprotein J/clusterin in human erythrocytes is involved in the molecular process of defected material disposal during vesiculation, PLoS ONE, 6, e26033, 10.1371/journal.pone.0026033 Devauchelle, 2004, Clusterin, a potential pathophysiological actor in rheumatoid arthritis, Arthritis Research & Therapy, 6, 68, 10.1186/ar1404 Derici, 2008, Does the urinary excretion of α1-microglobulin and albumin predict clinical disease activity in ulcerative colitis?, Advances in Therapy, 25, 1342, 10.1007/s12325-008-0109-8 Newcomer, 2000, Plasma retinol binding protein: structure and function of the prototypic lipocalin, Biochimica et Biophysica Acta, 1482, 57, 10.1016/S0167-4838(00)00150-3 Ronne, 1983, Ligand-dependent regulation of intracellular protein transport: effect of vitamin a on the secretion of the retinol-binding protein, The Journal of Cell Biology, 96, 907, 10.1083/jcb.96.3.907 Kanai, 1968, Retinol-binding protein: the transport protein for vitamin A in human plasma, Journal of Clinical Investigation, 47, 2025, 10.1172/JCI105889 Soggiu, 2012, A discovery-phase urine proteomics investigation in type 1 diabetes, Acta Diabetol, 49, 453, 10.1007/s00592-012-0407-0 Main, 1983, Vitamin A deficiency in Crohn's disease, Gut, 24, 1169, 10.1136/gut.24.12.1169 Barazzoni, 2011, High plasma retinol binding protein 4 (RBP4) is associated with systemic inflammation independently of low RBP4 adipose expression and is normalized by transplantation in nonobese: nondiabetic patients with chronic kidney disease, Clinical Endocrinology, 75, 56, 10.1111/j.1365-2265.2011.03990.x Keicho, 2012, Circulating levels of adiponectin, leptin, fetuin-A and retinol-binding protein in patients with tuberculosis: markers of metabolism and inflammation, PLoS ONE, 7, e38703, 10.1371/journal.pone.0038703 Olsen, 2009, Isolation of Mycobacterium avium subspecies paratuberculosis reactive CD4 T cells from intestinal biopsies of Crohn's disease patients, PLoS ONE, 4, e5641, 10.1371/journal.pone.0005641 Roncada, 2012, Farm animal milk proteomics, Journal of Proteomics, 75, 4259, 10.1016/j.jprot.2012.05.028 Piras, 2011, Comparative proteomics to evaluate multi drug resistance in Escherichia coli, Molecular BioSystems Reimund, 2005, Immune activation and nutritional status in adult Crohn's disease patients, Digestive and Liver Disease, 37, 424, 10.1016/j.dld.2005.01.010 Kupčová, 2003, Changes in acute phase proteins after anti-tumor necrosis factor antibody (infliximab) treatment in patients with Crohns disease, Physiological Research, 52, 89, 10.33549/physiolres.930290 Doherty, 1998, Analysis of changes in acute-phase plasma proteins in an acute inflammatory response and in rheumatoid arthritis using two-dimensional gel electrophoresis, Electrophoresis, 19, 355, 10.1002/elps.1150190234 Vascotto, 2007, Oxidized transthyretin in amniotic fluid as an early marker of preeclampsia, Journal of Proteome Research, 6, 160, 10.1021/pr060315z Rhodes, 2006, Lessons for inflammatory bowel disease from rheumatology, Digestive and Liver Disease, 38, 157, 10.1016/j.dld.2005.09.020 Cylwik, 2010, Relationship between serum acute-phase proteins and high disease activity in patients with rheumatoid arthritis, Advances in Medical Sciences, 55, 80, 10.2478/v10039-010-0006-7 Lundgren, 2010, Identification of complement C3 as an autoantigen in inflammatory bowel disease, European Journal of Gastroenterology & Hepatology, 22, 429, 10.1097/MEG.0b013e32833283b1 Kim, 2014, Identification of plasma Complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach, Journal of Proteomics, 96, 1, 10.1016/j.jprot.2013.10.032 Goldknopf, 2006, Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease, Biochemical and Biophysical Research Communications, 342, 1034, 10.1016/j.bbrc.2006.02.051 Hanas, 2008, Biomarker identification in human pancreatic cancer sera, Pancreas, 36, 61, 10.1097/mpa.0b013e3180d0a738 Urbani, 2012, Integrative proteomics: perspective in complex system interpretation, Molecular BioSystems, 8, 951, 10.1039/c2mb90009b